- CPGJ602 plus mFOLFOX6 as first-line treatment for patients with KRAS/NRAS/BRAF wild-type metastatic colorectal cancer: A randomized phase II study.Xu, Jianming; Cao, Bangwei; Gu, Kangsheng; Bai, Yuxian; Li, Wei; Zhang, Jingdong; Liu, Caigang; Niu, Zuoxing; Zhang, Liangming; Zhong, Haijun; Luo, Suxia; Zhou, Jian-Wei; Liu, Tianshu; Gu, Yanhong; Lin, Jingguan; Deng, Yanhong; Chen, Chuangqi; Li, Yunfeng; Yang, Xiuli; Li, BihuiAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III studyXu, R-H.; Qiu, M.; Bai, Y.; Wang, J.; Gu, K.; Yang, M.; He, Y.; Yi, C.; Jin, Y.; Liu, B.; Wang, F.; Huang, C.; Jiang, Y.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancerWang, F.; Xiao, J.; Zhang, Y.; Yuan, X.; He, M.; Fang, W.; Zhang, Y.; Wang, W.; Hu, X.; Ma, Z.; Yao, Y.; Zhuang, Z.; Zhou, F.; Ying, J.; Yuan, Y.; Zou, Q.; Guo, Z.; Wu, X.; Jin, Y.; Mai, Z.; Guo, Y.; Xu, R.ESMO 24th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2022-06-29 To 2022.
期刊论文
Metformin plus lrinotecan in patients with refractory colorectal cancer: a phase 2 clinical trial
21阅读
